Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119439 · ClinicalTrials.gov registry record · Phase 4
Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
A Phase 4 study, sponsored by Gynuity Health Projects.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT05119439: Clinical Trial Phase 4 study, sponsored by Gynuity Health Projects.
NCT05119439 is a Phase 4 study that was terminated before completion, run by Gynuity Health Projects. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05119439, a Phase 4 study, was terminated before completion, sponsored by Gynuity Health Projects.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study seeks to evaluate the efficacy, side effect profile and acceptability of a medical abortion regimen with mifepristone and two doses of 800 mcg misoprostol buccally at 71-77 and 78-84 days of gestation to further expand the evidence base for the most effective regimens in the late first trimester of pregnancy.
Primary Outcome
Proportion of women who achieve complete abortion with medication only and without aspiration or D\&E
Interventions
- DRUG Mifepristone + 2 doses of misoprostol 800 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-10-07 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 4 |
Why NCT05119439 stopped before completion
NCT05119439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Mifepristone + 2 doses of misoprostol 800 mcg is the first listed.
NCT05119439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05119439 about?
NCT05119439 is a clinical study titled "Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks". This study seeks to evaluate the efficacy, side effect profile and acceptability of a medical abortion regimen with mifepristone and two doses of 800 mcg misoprostol buccally at 71-77 and 78-84 days of gestation to further expand the evidence base for the most effective regimens in the late first tr...
What is the current status of trial NCT05119439?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2022-10-07. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05119439?
The interventions under investigation include: Mifepristone + 2 doses of misoprostol 800 mcg (DRUG).
Who is sponsoring clinical trial NCT05119439?
This trial is sponsored by Gynuity Health Projects, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05119439's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI